Altimmune, Inc. (NASDAQ:ALT) is a biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies, and vaccines. The company is gaining attention due to recent insider activity and analyst interest. On December 22, 2025, Durso Jerome Benedict, a director at Altimmune, purchased 12,500 shares at $4.13 each, as reported on Form 4. This insider purchase may indicate confidence in the company's future prospects.
Wall Street analysts have set a mean price target of $17.88 for Altimmune, suggesting a potential upside of 229.3% from its last closing price of $5.43. This optimistic outlook is supported by a recent 28.4% gain in the stock over the past four weeks. However, price targets vary significantly, ranging from $1.00 to $28.00, with a standard deviation of $8.81. This variability highlights differing expectations among analysts.
Currently, Altimmune's stock is priced at $4.14, reflecting a 6.15% increase today with a price change of $0.24. The stock has fluctuated between $3.95 and $4.44 during the trading day. Over the past year, it has reached a high of $8.25 and a low of $2.90. The company's market capitalization is approximately $365.4 million, with a trading volume of 6,850,798 shares.
Despite the allure of the consensus price target, investors are advised to consider other factors before making investment decisions. An upward trend in earnings estimate revisions could signal further upside for Altimmune in the near term. However, the lowest analyst estimate suggests a potential decline of 81.6%, while the most optimistic forecast points to a possible 415.7% increase, indicating a wide range of potential outcomes.
